within Pharmacolibrary.Drugs.R_RespiratorySystem.R03C_AdrenergicsForSystemicUse.R03CB02_Methoxyphenamine;

model Methoxyphenamine
  extends Pharmacolibrary.Drugs.ATC.R.R03CB02;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>R03CB02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Methoxyphenamine is a sympathomimetic amine and derivative of amphetamine, structurally related to the drug methamphetamine. It was once used as a bronchodilator and decongestant for the treatment of asthma and allergic rhinitis, but it is rarely used or approved today due to the availability of newer, safer alternatives.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adult humans via oral administration, as no clinical PK publication could be identified.</p><h4>References</h4><ol><li><p>Foster, BC, et al., &amp; Buttar, HS (1995). The influence of pregnancy on the biotransformation and urinary excretion of methoxyphenamine in mice. <i>Biopharmaceutics &amp; drug disposition</i> 16(1) 1–11. DOI:<a href=\"https://doi.org/10.1002/bdd.2510160102\">10.1002/bdd.2510160102</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7711279/\">https://pubmed.ncbi.nlm.nih.gov/7711279</a></p></li><li><p>Muralidharan, G, et al., &amp; Midha, KK (1996). Quinidine inhibits the 7-hydroxylation of chlorpromazine in extensive metabolisers of debrisoquine. <i>European journal of clinical pharmacology</i> 50(1-2) 121–128. DOI:<a href=\"https://doi.org/10.1007/s002280050079\">10.1007/s002280050079</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8739822/\">https://pubmed.ncbi.nlm.nih.gov/8739822</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Methoxyphenamine;
